Danaher
DHR
Performance
About Danaher
Danaher is a global leader in life sciences and diagnostics, dedicated to accelerating the power of science and technology to improve human health. The company operates through biotechnology, diagnostics, and life sciences businesses, developing tools, technologies, and services that advance therapies, research, and patient care. Danaher emphasizes a continuous improvement culture via the Danaher Business System to drive collaboration, acquisitions, and partnerships across its worldwide operations. Headquartered in Washington, D.C., USA, the group serves customers across healthcare, research institutions, and industrial markets.
Recent News
Jim Cramer's Top 10 Things to Watch in the Stock Market Friday
Apple Defeats Bid for New Apple Watch Import Ban at US Trade Tribunal
Danaher Corp (DHR) Q1 2026 Earnings Call Transcript
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
Some Implied Moves for Earnings Next Week(Apr. 20th – Apr. 24th) – 301 Companies Reporting
Lawhive Closes $60M Series B for Consumer Legal AI
Top 200 Collector Mitchell Rales Gifts $116 M. To National Gallery of Art for Lending Program
IDBS Celebrates Customer Successes and Product Innovations in 2025
Stock Market Records, Iran Updates, and Tesla Earnings: What to Watch This Week
Historic $116M Gift Endows Lending Program at National Gallery of Art
#58735
Chapters Group: German Conglomerate Aiming to Be the Next Berkshire Hathaway
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs Viral Infection Results in Approximately 20 Minutes
Lee Ainslie: Concentrating Capital in AI Leaders While Pruning Legacy Positions
Lawhive Raises $60M in Series B Funding
Danaher Reaches $172.5M Settlement With Shareholders Over Post-Pandemic Outlook
Automata Secures $45M Series C to Build the Operating System for AI-Ready Labs
Lee Ainslie Portfolio Analysis: Key Positions, AI Bets & Maverick Capital Strategy
Siemens Healthineers Appoints New Chief Technology Officer
Sources: US Healthcare Manufacturer Danaher Is Nearing a Deal to Buy Medtech Company Masimo for ~$10B; Masimo Is in an IP Dispute with Apple over Apple Watch (Financial Times)
Future-Ready Pharma Summit